SCHEMBL22191163

SCHEMBL22191163

Cn1c(=O)[nH]c2cc(-c3cnc(NCc4ccccc4)nc3)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PGR P06401 2/20 0.45
▸ MAOB P27338 2/20 0.44
▸ GAA P10253 2/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ VNN1 O95497 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GRIN1 Q05586 1/20 0.40
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22191015 0.92 PGR (0.50) DYRK1ALMNAPGRMAOBGAA
SCHEMBL22191346 0.89 DYRK1A (0.48) DYRK1ALMNAGAAADORA2AADORA2B
SCHEMBL22191654 0.83 DYRK1A (0.45) DYRK1ALMNAPGRMAOBMAPT
SCHEMBL22191084 0.82 PGR (0.55) LMNAPGRMAOBVNN1TSHR
SCHEMBL29437819 0.81 DYRK1A (0.49) DYRK1APGRMAOBGAAADORA2A
SCHEMBL22191187 0.81 DYRK1A (0.49) DYRK1APGRMAOBGAAADORA2A
SCHEMBL22191095 0.80 PLK4 (0.50) DYRK1AGAAMAPTVNN1
SCHEMBL22190880 0.80 PGR (0.56) PGRMAOB
SCHEMBL22191186 0.80 PGR (0.48) DYRK1ALMNAPGRVNN1L3MBTL1
SCHEMBL29437808 0.80 PGR (0.48) DYRK1ALMNAPGRVNN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-03 — — US disclosed
EP-3906028-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 — — EP disclosed
CN-113543783-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2021-10-22 — — CN disclosed
WO-2020142486-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE CSNK1A1, MAP3K20, CSNK1G3 DYRK1A 479/4885LMNA 1712/4885PGR 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback